CCL5 and neoplasm: According to multivariate Cox regression analysis (adjusted for tumor stage, lymph node stage, chemotherapy, and molecular subtype), CCL5 positivity remained an independent prognostic marker for OS in the luminal molecular subtype subgroup (RR = 2.18; p = 0.010) and an independent prognostic marker for DSS in the following subgroups: tumor stage pT2 (RR = 3.69; p = 0.044), nodal stage N0 (RR = 1.92; p = 0.033), and tumors of the luminal molecular subtype subgroup (RR = 2.99; p = 0.002).